Clinical Trial Update: Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated whether dapagliflozin can prevent anthracycline-induced cardiotoxicity. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthracyclines-induced Cardiotoxicity
• Cardiotoxicity

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Hawler Medical University | Conditions: Anthracyclines-Induced Cardiotoxicity, Cardiotoxicity | Phase 2 | Status: COMPLETED